Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochem Soc Trans. 2004 Apr;32(Pt 2):393-6.

Inhibiting the phosphoinositide 3-kinase pathway for cancer treatment.

Author information

1
Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Sutton, Surrey SM2 5NG, U.K. paul.workman@icr.ac.uk

Abstract

There is extensive evidence from the molecular and genomic analysis of human cancers that the PI 3-kinase (phosphoinositide 3-kinase)-Akt/PKB (protein kinase B) pathway is deregulated in malignant progression. Furthermore, the causal involvement of PI 3-kinase is supported by gene-knockout mouse models. Prototype inhibitors show evidence of anticancer activity in vitro and in vivo animal models. The recent development of isoform-selective inhibitors shows considerable promise for cancer treatment.

PMID:
15046615
DOI:
10.1042/
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center